Molecular models of cyclin-dependent kinase 1 complexed with inhibitors

被引:44
|
作者
Canduri, F [1 ]
Uchoa, HB
de Azevedo, WF
机构
[1] UNESP, Dept Fis, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil
[2] UNESP, Programa Posgrad Biofis Mol, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil
[3] Ctr Appl Toxicol, Inst Butantan, BR-05503900 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
CDK; drug design; flavopiridol; roscovitine; homology modeling;
D O I
10.1016/j.bbrc.2004.09.109
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no crystallographic structure is available for complexes of CDK1 with inhibitors. The present work describes two molecular models for the binary complexes CDK1:roscovitine and CDK1:flavopiridol. These structural models indicate that both inhibitors strongly bind to the ATP-binding pocket of CDKI and structural comparison of the CDK complexes correlates the structures with differences in inhibition of these CDKs by flavopiridol and roscovitine. This article explains the structural basis for the observed differences in activity of these inhibitors. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:661 / 666
页数:6
相关论文
共 50 条
  • [1] Molecular models of cyclin-dependent kinase 4 complexed with indirubin and its analogues
    Zhang, N
    Jiang, YN
    Zou, JW
    Zeng, M
    Hu, GX
    Yu, QS
    [J]. ACTA CHIMICA SINICA, 2005, 63 (09) : 809 - 813
  • [2] Molecular modeling and dynamics simulation of human cyclin-dependent kinase 3 complexed with inhibitors
    Perez, Patricia Cardoso
    Caceres, Rafael A.
    Canduri, Fernanda
    de Azevedo, Walter Filgueira, Jr.
    [J]. COMPUTERS IN BIOLOGY AND MEDICINE, 2009, 39 (02) : 130 - 140
  • [3] Molecular model of cyclin-dependent kinase 5 complexed with roscovitine
    de Azevedo, WF
    Gaspar, RT
    Canduri, F
    Camera, JC
    da Silveira, NJF
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 297 (05) : 1154 - 1158
  • [4] Cyclin-dependent kinase inhibitors
    Westwell, A
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (09) : 491 - 491
  • [5] Cyclin-dependent kinase inhibitors
    Dai, Y
    Grant, S
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 362 - 370
  • [6] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    [J]. MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [7] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    [J]. Molecular Biotechnology, 2001, 19 : 179 - 188
  • [8] Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias
    Hayette, S
    Thomas, X
    Bertrand, Y
    Tigaud, I
    Callanan, M
    Thiebaut, A
    Charrin, C
    Archimbaud, E
    Magaud, JP
    Rimokh, R
    [J]. LEUKEMIA, 1997, 11 (10) : 1696 - 1699
  • [9] Novel cyclin-dependent kinase inhibitors
    Westwell, AD
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (13) : 701 - 701
  • [10] INHIBITORS OF CYCLIN-DEPENDENT KINASE AND CANCER
    BIGGS, JR
    KRAFT, AS
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (10): : 509 - 514